Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
Go back to Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1107.08 +5.00 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1102.08 | 52 Week High | $88.16 | |||
| Open | $1117.00 | 52 Week Low | $67.88 | |||
| Day High | $1122.02 | P/E | 256.27 | |||
| Day Low | $1079.22 | EPS | $4.32 | |||
| Volume | 3,314,672 | |||||
